Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 7;14:1095487. doi: 10.3389/fphar.2023.1095487

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Zeng, Huang, Zhang, Lv, Cheng, Zou, Han, Wang, Gong and Peng.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Dapagliflozin inhibited activation of the TGF-β1/MAPK pathway and attenuated the reductions of mitochondrial respiratory chain complexes in HK2 cells stimulated by TGF-β1. (A, B) Western blot showing the expression of p-JNK, p-ERK, and p-P38 in HK2 cells in each group. (C–E) Western blot showing the expression of mitochondrial respiratory chain complexes (oxphos) in HK2 cells in each group. Values are means ± SD. **p < 0.01 TGF-β1 stimulated group compared with the control group; ***p < 0.001 TGF-β1 stimulated group compared with the control group; #p < 0.05 dapagliflozin treatment group compared with the TGF-β1 stimulated group; ^## p < 0.01 dapagliflozin treatment group with the TGF-β1 stimulated group compared; ^### p < 0.001 dapagliflozin treatment group compared with the TGF-β1 stimulated group; and p < 0.01 20 μM dapagliflozin treatment group compared with the 40 μM dapagliflozin treatment group.